4//SEC Filing
SHANGHVI DILIP S 4
Accession 0000899243-17-027391
CIK 0001604950other
Filed
Nov 23, 7:00 PM ET
Accepted
Nov 24, 4:33 PM ET
Size
19.8 KB
Accession
0000899243-17-027391
Insider Transaction Report
Form 4
SUN PHARMACEUTICAL INDUSTRIES LTD
10% Owner
Transactions
- Conversion
Common Stock
2017-11-21+1,810,536→ 1,810,536 total(indirect: By Sun Pharmaceutical Industries, Inc.) - Conversion
Series B Preferred Stock
2017-11-21−13,000,000→ 0 total(indirect: By Sun Pharmaceutical Industries, Inc.)→ Common Stock (1,810,536 underlying) - Purchase
Common Stock
2017-11-21$14.00/sh+357,143$5,000,002→ 357,143 total(indirect: By Sun Pharma (Netherlands) B.V.)
Sun Pharma (Netherlands) B.V.
10% Owner
Transactions
- Conversion
Series B Preferred Stock
2017-11-21−13,000,000→ 0 total(indirect: By Sun Pharmaceutical Industries, Inc.)→ Common Stock (1,810,536 underlying) - Conversion
Common Stock
2017-11-21+1,810,536→ 1,810,536 total(indirect: By Sun Pharmaceutical Industries, Inc.) - Purchase
Common Stock
2017-11-21$14.00/sh+357,143$5,000,002→ 357,143 total(indirect: By Sun Pharma (Netherlands) B.V.)
Sun Pharmaceutical Industries, Inc.
10% Owner
Transactions
- Purchase
Common Stock
2017-11-21$14.00/sh+357,143$5,000,002→ 357,143 total(indirect: By Sun Pharma (Netherlands) B.V.) - Conversion
Series B Preferred Stock
2017-11-21−13,000,000→ 0 total(indirect: By Sun Pharmaceutical Industries, Inc.)→ Common Stock (1,810,536 underlying) - Conversion
Common Stock
2017-11-21+1,810,536→ 1,810,536 total(indirect: By Sun Pharmaceutical Industries, Inc.)
SHANGHVI DILIP S
10% Owner
Transactions
- Purchase
Common Stock
2017-11-21$14.00/sh+357,143$5,000,002→ 357,143 total(indirect: By Sun Pharma (Netherlands) B.V.) - Conversion
Series B Preferred Stock
2017-11-21−13,000,000→ 0 total(indirect: By Sun Pharmaceutical Industries, Inc.)→ Common Stock (1,810,536 underlying) - Conversion
Common Stock
2017-11-21+1,810,536→ 1,810,536 total(indirect: By Sun Pharmaceutical Industries, Inc.)
Footnotes (4)
- [F1]Represents the total number of shares of Common Stock received by Sun Pharmaceutical Industries, Inc. upon conversion of the Issuer's Series B Preferred Stock in connection with the closing of the Issuer's initial public offering.
- [F2]Sun Pharmaceutical Industries Limited ("Sun Pharma") directly and indirectly owns all shares of Sun Pharmaceutical Industries, Inc., which is the registered owner of the securities. Sun Pharma may be deemed to beneficially own all of the shares of the Issuer held by Sun Pharmaceutical Industries, Inc. Dilip S. Shanghvi is the controlling shareholder of Sun Pharma. Sun Pharma and Mr. Shanghvi disclaim beneficial ownership of the reported shares except to the extent of their respective pecuniary interests therein.
- [F3]Sun Pharma is the sole shareholder of Sun Pharma (Netherlands) B.V., which is the registered owner of the securities. Sun Pharma may be deemed to beneficially own all of the shares of the Issuer held by Sun Pharma (Netherlands) B.V. Dilip S. Shanghvi is the controlling shareholder of Sun Pharma. Sun Pharma and Mr. Shanghvi disclaim beneficial ownership of the reported shares except to the extent of their respective pecuniary interests therein.
- [F4]All series of the Issuer's Series B Preferred Stock automatically converted into the Issuer's Common Stock on a 7.180193-for-1 basis on November 21, 2017. The Series B Preferred Stock had no expiration date.
Issuer
scPharmaceuticals Inc.
CIK 0001604950
Entity typeother
Related Parties
1- filerCIK 0001249644
Filing Metadata
- Form type
- 4
- Filed
- Nov 23, 7:00 PM ET
- Accepted
- Nov 24, 4:33 PM ET
- Size
- 19.8 KB